RCLL Financials Monday, July 14, 2014 12:26:45 PM
RegenoCell Therapeutics, Inc.
Period Ending Dec 31, 2011 Dec 31, 2010
Total Revenue 865 910
Cost of Revenue 127 92
Gross Profit 738 818
Operating Expenses
Research and Development - -
Sales, General and Admin. 1,537 1,573
Non-Recurring Items - 2,741
Other 64 59
Operating Income (863) (3,555)
Income From Continuing Operations
Add'l Income/Expense Items 8 105
Earnings Before Interest and Tax (855) (3,450)
Interest Expense 441 360
Earnings Before Tax (1,296) (3,811)
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (1,297) (3,811)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (1,296) (3,811)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (1,296) (3,811)